TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · no major macro event
QURE

Uniqure NV

Healthcare · Biotechnology · listed since 2007

23.80$ -3.3% vs. previous close Closing price · As of: Nov 13, 2026
🔔 Watch stock
Add to watchlist

Share this page

LinkedIn WhatsApp Email

Assessment

Our Rating

A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.

Open questions

The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.

Why this colour

Yellow, because the company’s fate hinges on a single event — the FDA’s decision on AMT-130 by May 1, 2027 — without a documented threat to its substance. Against green: apart from the one-time HEMGENIX sale in 2021, uniQure has never been profitable, a revenue base of its own is missing, the application rests on twelve high-dose patients versus an external control, and the agency has changed its stance on that data twice. Clearly against red: $810.3 million in cash against $178.0 million in operating cash outflow in 2025 means about four and a half years of runway on paper, equity is positive at $324.1 million, the report contains no going-concern doubt, and the $495.1 million royalty liability only has to be serviced from HEMGENIX income. That the stock has lost half its value since June 2026 is a question of price, not quality. The next milestones are the advisory committee date and the start of the confirmatory study. The decision is yours.

What the thesis turns on

Assessment: Opportunities & Risks

uniQure is a well-funded gene therapy company with $810.3 million in cash whose Huntington’s therapy AMT-130 has been under FDA review since November 2, 2026 (target date May 1, 2027). The evidence is thin and was disputed within the agency itself, the primary endpoint missed significance after four years, there is hardly any revenue of its own, and the share count has risen 41.6 percent since the end of 2024. At $22.97 (November 2, 2026), cash covers about half of the market value. Not investment advice.

Funding

As of June 30, 2026, uniQure held $810.3 million in cash and current investment securities; according to the quarterly report, that lasts into 2030. Operating cash outflow was $178.0 million in 2025 and $66.8 million in the first half of 2026. Upon approval before September 30, 2027, up to $100 million in additional credit becomes available.

AMT-130 evidence

The application rests on twelve high-dose patients at 36 months compared with an external control from the Enroll-HD database. At 48 months, the primary endpoint cUHDRS missed significance with 44 percent slowing (p=0.144); everyday functioning showed 61 percent (nominal p=0.008).

Regulatory process

The FDA accepted the application with priority review on November 2, 2026, target date May 1, 2027, and an advisory committee is tentatively planned. Before that, it changed its stance on the same data in November 2025, early 2026 and June 2026. Accelerated approval requires a confirmatory study with about 200 patients.

Revenue base

uniQure generated only $16.1 million in 2025 revenue from HEMGENIX royalties against a $199.0 million net loss. In the first half of 2026, $9.4 million in revenue was matched by $9.2 million in payments to the royalty buyer, whose claim runs up to $693.8 million through mid-2032.

Dilution

The share count rose 41.6 percent from December 31, 2024, to July 24, 2026, to 69.37 million, most recently through the June 2026 offering at $45.50. Another 8.04 million potential shares are outstanding; authorized capital was raised to 100 million shares.

Worth Noting

uniQure made our research list through the Reddit hype scanner (mentions in Reddit forums). We reviewed the annual reports (10-K) for 2025 (filed 03/02/2026) and 2024 (02/27/2025), the quarterly reports (10-Q) for 03/31/2026 and 06/30/2026 (07/29/2026), the earnings release (8-K Item 2.02, Exhibit 99.1) of 07/29/2026, and every filing since: S-8 of 07/29/2026, Schedule 13G/13G-A of 08/14 and 10/16/2026 (passive stakes), 8-Ks of 09/02/2026 (U.S. and U.K. applications), 09/29/2026 (four-year data) and 11/02/2026 (BLA acceptance). Last insider filing (Form 4) on 07/07/2026. No 10-Q for 09/30/2026 had been filed as of 11/03/2026.

Our own calculations from reported figures: 69,366,412 shares (07/24/2026) vs. 48,988,087 (12/31/2024) = up 41.6%; 8,039,069 potential shares (06/30/2026) = about 11.6% of shares outstanding; market value 69,366,412 × $22.97 = about $1.593 billion (identical to the fundamental data figure); $1.593 billion minus $810.3 million cash plus the $50.0 million Hercules loan = about $830 million; cash runway $810.3 million / $178.0 million = about 4.5 years at the 2025 pace; CEO sales 06/17–07/02/2026 per Form 4: 262,594 shares, about $12.1 million in total.

Data gaps named openly: no P/E (loss); price-to-sales and Altman Z (fundamental data: −0.6) say little about a research company without product revenue; reporting currency U.S. dollars with many euro obligations, hence currency effects in earnings (2025: +$26.1 million, Q2 2026: −$1.7 million). Risk of confusion: AMT-130 and ifezuntirgene inilparvovec are the same therapy; HEMGENIX is sold by CSL Behring, not uniQure. Analyses are evergreen; daily prices are not a reason to buy.

Stock Watch

This analysis is as of November 3, 2026. Stock Watch will tell you what's changed at QURE since then.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 9.00 $ to 51.10 $ · Last price: 23.80 $ (As of: November 13, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 1.7$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 70m
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 83.1%
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. 1.1

Performance

Perf. 1M ?Price performance over the last month. 9.50%
Perf. 3M ?Price performance over the last 3 months. 62.80%
Perf. 6M ?Price performance over the last 6 months. 72.70%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). 88.05%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -36.3%
Perf. 1Y ?Price performance over the last 12 months. -21.52%
Perf. 3Y ?Price performance over the last 3 years. 296.83%
Perf. 5Y ?Price performance over the last 5 years. -25.52%
Perf. 10Y ?Price performance over the last 10 years. 192.51%
Perf. Since Inception ?Price performance since the first available trading day (02/05/2014) — with a complete history, that is since the IPO. 62.97%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 24.80$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 29.50$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 29.60$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 45.7
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 69.7%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 125.8%

Calculated from the price history · as of 11/14/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E. –
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. 27.9
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey. –
P/B ?Price-to-book ratio: market value relative to book equity. 5.2
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. 81.8
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. 1.4
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up. –

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. -559.9%
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. -872.2%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. 0.0%
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? -157.6%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). -13.7%

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. 24.1%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 0.3
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. warning zone 0.87
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. 5 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). 11.00%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). -18.20%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. -40.64%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. -66.15%
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. -17.50%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. –
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. –
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. –
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. D (36 out of 100)

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Biotechnology

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
Uniqure NV QURE 1.7 – 1.4 -559.9 -872.2 -40.6 -21.5
Vertex Pharmaceuticals Inc VRTX 136.2 32.1 27.5 54.8 38.1 9.6 24.0
Regeneron Pharmaceuticals Inc REGN 99.3 24.1 14.1 46.7 20.7 1.0 38.2
Moderna Inc MRNA 88.6 – 4.6 -66.0 -131.1 -39.2 794.9
argenx NV ARGX 59.7 36.7 27.6 59.8 32.0 89.6 7.7
BeiGene, Ltd. ONC 47.1 74.4 29.5 89.4 19.1 40.2 10.2
Royalty Pharma Plc RPRX 38.2 37.5 24.0 99.8 100.3 5.1 78.4
Revolution Medicines Inc RVMD 35.8 – -9.7 -174,708.6 0.0 -100.0 167.6
Genmab AS GMAB 32.0 40.4 28.6 92.7 35.2 -82.7 69.9
Median of companies shown 47.1 37.1 24.0 54.8 20.7 1.0 38.2

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Fiscal years

Annual Figures

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

Revenue, operating income and net income per fiscal year $M

Revenue Operating income Net income

2016 · Revenue: 25 $M 2016 · Operating income: -72 $M 2016 · Net income: -73 $M 2017 · Revenue: 13 $M 2017 · Operating income: -72 $M 2017 · Net income: -80 $M 2018 · Revenue: 11 $M 2018 · Operating income: -88 $M 2018 · Net income: -83 $M 2019 · Revenue: 7 $M 2019 · Operating income: -121 $M 2019 · Net income: -124 $M 2020 · Revenue: 38 $M 2020 · Operating income: -125 $M 2020 · Net income: -125 $M 2021 · Revenue: 524 $M 2021 · Operating income: 311 $M 2021 · Net income: 330 $M 2022 · Revenue: 106 $M 2022 · Operating income: -143 $M 2022 · Net income: -127 $M 2023 · Revenue: 16 $M 2023 · Operating income: -283 $M 2023 · Net income: -308 $M 2024 · Revenue: 27 $M 2024 · Operating income: -184 $M 2024 · Net income: -240 $M 2025 · Revenue: 16 $M 2025 · Operating income: -188 $M 2025 · Net income: -199 $M
2016201720182019202020212022202320242025
Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 25 -72 -73 -2.93 -72 64 190
2017 13 -72 -80 -2.98 -64 90 209
2018 11 -88 -83 -2.34 -76 180 274
2019 7 -121 -124 -3.11 -99 323 449
2020 38 -125 -125 -2.81 -135 244 340
2021 524 311 330 7.04 288 596 809
2022 106 -143 -127 -2.71 -145 476 705
2023 16 -283 -308 -6.47 -146 208 832
2024 27 -184 -240 -4.92 -183 -7 557
2025 16 -188 -199 -3.46 -178 199 825

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q3 · 2.3 $M Q3 2024: Q4 · 5.2 $M Q4 2025: Q1 · 1.6 $M Q1 2025: Q2 · 5.3 $M Q2 2025: Q3 · 3.7 $M Q3 2025: Q4 · 5.6 $M Q4 2026: Q1 · 3.6 $M Q1 2026: Q2 · 5.8 $M Q2 2026: Q3 · 5.2 $M Q3

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q3 -0.84 52.00 2 62.50 -1,940.40 -37 -45
2024: Q4 -1.50 2.00 5 -21.90 -1,403.20 -53 -53
2025: Q1 -0.82 39.70 2 -81.50 -2,784.70 -44 -44
2025: Q2 -0.69 40.50 5 -52.70 -716.80 -40 -40
2025: Q3 -1.38 -64.30 4 61.80 -2,175.90 -16 -17
2025: Q4 -0.47 68.40 6 6.60 -666.10 -78 -78
2026: Q1 -0.85 -3.70 4 127.30 -1,502.90 -38 -38
2026: Q2 -1.22 -76.80 6 11.00 -1,387.80 -29 -29
2026: Q3 -0.88 36.20 5 40.50 -1,176.90 -48 -48

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Screening

Appears in These Scanners

This stock currently matches 4 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet

Momentum & Trend

Research

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus Strong Sell 1 = Strong buy … 5 = Strong sell
Analyst Ratings 13
Price Target (average) 60.23$
Distance to price 153.1% The price target sits 153.1% above the current price.

Distribution of Recommendations

Strong Buy 10
Buy 1
Hold 2
Sell 0
Strong Sell 0

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 -3.30 -3.47 – -3.12 19 -12.8% 8
12/31/2027 -2.84 -3.83 – -0.52 112 14.0% 10

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Valuation

What is priced in?

Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.

A simplified model calculation — not a forecast and not a recommendation.

AI classification

AI Rating

Neutral

Geprüft am 03.11.2026 gegen die Geschäftsberichte (10-K) 2025 (eingereicht 02.03.2026) und 2024 (27.02.2025) sowie die vier jüngsten Quartalsberichte (10-Q) bis zum 30.06.2026: In den ausgewerteten SEC-Filings von uniQure findet sich kein wesentlicher KI-Bezug. Die einzigen Erwähnungen von „artificial intelligence“ stehen in einem Compliance-Risikofaktor des 10-K 2025 zu Datenschutz- und KI-Regulierung („We are subject to laws governing data protection and artificial intelligence (“AI”) in the different jurisdictions in which we operate.“ — „Wir unterliegen in den verschiedenen Rechtsordnungen, in denen wir tätig sind, Gesetzen zum Datenschutz und zur künstlichen Intelligenz (KI).“), ergänzt um einen Hinweis auf die Pflichten aus dem EU AI Act. Das ist weder eine KI-Umsatzquelle noch ein belegter operativer KI-Einsatz noch ein konkretes KI-Risiko für das eigene Geschäftsmodell der Gentherapie-Firma (AMT-130 gegen Huntington, Lizenzerlöse aus HEMGENIX); die übrigen fünf Filings enthalten keinen KI-Treffer. Nach dem Kriterienkatalog: neutral.

View the full file — quotes, sources, reviewed filings

Filings Reviewed: 10-Q 2026-07-29 · 10-Q 2026-05-05 · 10-Q 2025-11-10 · 10-Q 2025-07-29 · 10-K 2026-03-02 · 10-K 2025-02-27

Rated on November 3, 2026 · How the Rating Is Built

Growth

Growth Score

Ten checks against the annual reports — each one passed counts a point.

2 of 10 Weak growth
  • Revenue grows by more than 15% a year over three years -46.7%
  • More than 10% revenue growth is expected for the coming year -66.2%
  • Share count grows by less than 3% a year 7.2%
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -1,148.9%
  • Gross margin at 40% or higher and without meaningful erosion 89.5%
  • Goodwill from acquisitions does not grow faster than revenue 3.1%
  • Net debt below twice EBITDA 86 m net cash
  • Operating cash flow covers the profits of the last three years 240 m
  • Return on capital at 15% or higher, or up versus two years ago -24.7%
  • Insiders hold at least 10% or are net buyers 1.3%

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Quality check

AAQS

4/10

The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).

  • Sales growth 10Y > 5% -4.8%
  • Exp. sales growth 3Y > 5% 163.8%
  • EBIT growth 10Y > 5% –
  • Exp. EBIT growth 3Y > 5% 163.8%
  • Net debt < 4x EBIT –
  • EBIT positive, 10Y straight 1
  • Max. EBIT decline < 50% 100.0%
  • Return on equity > 15% -197.5%
  • ROCE > 15% -24.6%
  • Expected return > 10% 135.3%

View stocks with the full AAQS score · Read the methodology at AlleAktien

Source: fundamental data

Insiders

Insider Transactions

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

Insider Transactions
Date Person Role Type Shares Price Value
Nov 6, 2026 Meek David D. Director Sell 9,080 21.25 192,950
Oct 30, 2026 Abi-Saab Walid Chief Medical Officer Other 18,750 0.00 –

View all insider transactions →

The company

About the Company

uniQure N.V. entwickelt Behandlungen für Patienten, die an seltenen und anderen schweren Erkrankungen leiden, in den Vereinigten Staaten. Das Unternehmen bietet HEMGENIX an, das es Menschen mit Hämophilie B ermöglicht, Faktor IX zu produzieren, wodurch sich das Blutungsrisiko senken lässt. Sein führender Produktkandidat ist AMT-130, ein Gentherapiekandidat, der sich in einer Phase-I/II-Studie zur Behandlung der Huntington-Krankheit befindet. Das Unternehmen entwickelt zudem AMT-260, das sich in einer Phase-I/IIa-Studie zur Behandlung der mesialen Temporallappenepilepsie befindet; AMT-162, das sich in einer Phase-I/IIa-Studie zur Behandlung der Superoxid-Dismutase-Enzym-assoziierten amyotrophen Lateralsklerose befindet; sowie AMT-191, einen experimentellen Gentherapiekandidaten, der sich in einer Phase-I/IIa-Studie zur Behandlung von Morbus Fabry befindet. Es hat eine Lizenzvereinbarung mit Apic Bio zur Entwicklung, Herstellung und Vermarktung einer intrathekal verabreichten experimentellen Gentherapie für ALS, die durch Mutationen in SOD-1 verursacht wird; sowie eine Entwicklungs- und Lieferabkommen mit CLS Behring für die kommerzielle Versorgung. uniQure N.V. wurde 1998 gegründet und hat seinen Hauptsitz in Amsterdam, Niederlande.

Employees
221
Headquarters
Amsterdam, Netherlands
Address
Paasheuvelweg 25, 1105 BP Amsterdam, Netherlands
Phone
31 20 240 6000
IPO Date
06/20/2007
ISIN
NL0010696654
Stock Split
1:5 on 01/31/2014

Management

Management
Name Title Birth Year
Matthew Craig Kapusta CPA CEO & Executive Director 1972
Christian Klemt CFO, Principal Financial Officer & GM of Amsterdam Site 1973
Jeannette Potts J.D., Ph.D. Chief Legal & Compliance Officer and Corporate Secretary 1962
Walid Abi-Saab M.D. Chief Medical Officer 1965
Prof. Hugo Katus Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany –
Amin Abujoub Ph.D. Chief Technical Operations Officer –
Richard Porter Ph.D. Chief Business & Scientific Officer 1968
Chiara Elizabeth Russo Senior Director of Investor Relations –
Tamara Tugal Ph.D., MBA Business Development Director –
Erin Boyer Chief People & Culture Officer –

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Filings

Company Filings (8-K)

An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).

  • 11/04/2026 uniQure N.V. (QURE): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
  • 11/02/2026 uniQure N.V. (QURE): Regulation FD Disclosure; Other Events; Financial Statements and Exhibits SEC ↗
  • 09/29/2026 uniQure N.V. (QURE): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
  • 09/02/2026 uniQure N.V. (QURE): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗

Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?